A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans

Table 2 Peptides affected by drug treatment

Peptide	Protein	p		Time at maximum decrease (h)	% maximum decrease
Peptide	Protein	140 mg	280 mg	Time at maximum decrease (h)	% maximum decrease
EDVGSNK	Amyloid Precursor Protein and Amyloid beta A4 protein^ab	0.36	0.0035	9	42
DELAPAGTGVSREAVSG	Amyloid-like protein 1^ab	0.077	0.0018	12	32
SVQPDSPTDVNQENVPS	Tachykinin-3	0.065	0.0041	9	38
VTEDDEDEDDDKE	Testican-1	0.25	0.0039	18	26
AVTEDDEDE	Testican-1	0.065	0.0025	18	19
DDEDEDDDKE	Testican-1	0.41	0.0039	18	26
EKLPGQGVHSQGQGPGAN	Golgi apparatus protein 1^a	0.11	0.0020	18	20
DFLAEGGGVR	Fibrinogen alpha chain	0.66	0.0024	9	36
EPPPPPEPA	CD99 antigen-like protein 2^a	0.69	0.0041	18	24
TVVQPSVGAAAGPVVPPCPGRIRHFKV	Alpha-2-HS-glycoprotein	0.86	0.0039	9	27
DPNCSCATGGSCTCAGSCKCKE	Metallothionein-1E	-	0.0050	12	42

Endogenous CSF peptides that decreased in abundance after treatment with semagacestat
CSF cerebrospinal fluid
^atransmembrane protein
^bpreviously reported gamma secretase substrate

ISSN: 1758-9193